Sepsis News and Research

Latest Sepsis News and Research

HealthGrades America’s 50 Best Hospitals for 2010 identified

The HealthGrades America’s 50 Best Hospitals for 2010 were identified in a report issued today by the leading independent healthcare ratings organization. The analysis, which examined objective patient outcomes over three years at all 5,000 of the nation’s nonfederal hospitals, found that the 50 Best Hospitals had mortality rates that were, on average, 27% lower than other hospitals.

25 Feb 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

A comparison of two strategies for treating severe sepsis or septic shock finds that using lactate levels measured in blood samples showed a similar short-term survival rate compared to a treatment regimen using central venous oxygen saturation measured using a specialized catheter, according to a study in the February 24 issue of JAMA.

24 Feb 2010

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Good Samaritan Hospital in Los Angeles is named as One of America’s 50 Best Hospitals in 2010 by HealthGrades, Inc., the nation’s leading independent healthcare ratings organization.

24 Feb 2010

Study says lower-cost hospitals don't have lower quality care for certain illnesses

A study Monday in the Archives of Internal Medicine found little difference in outcomes between hospitals with longer patient stays and shorter ones, which could make it "possible to lower costs in the U.S. system without hurting patients," Reuters reports.

24 Feb 2010

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Current research suggests that nitric oxide may play a role in the pathogenesis of neonatal meningitis. The related report by Mittal et al, "Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis," appears in the March 2010 issue of The American Journal of Pathology.

24 Feb 2010

Multidisciplinary rounds may facilitate implementation of best clinical practices: Study

Multidisciplinary care teams consisting of clinicians, nurses and other health care professionals appear to be associated with a lower risk of death among patients in the intensive care unit, according to a report in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. A second report finds that an increasing number of surgical patients are being managed jointly by a surgeon and another clinician, such as a hospitalist or internal medicine sub-specialist.

23 Feb 2010

Hospital-acquired infections increase mortality rate and healthcare costs

Two common conditions caused by hospital-acquired infections (HAIs) killed 48,000 people and ramped up health care costs by $8.1 billion in 2006 alone, according to a study released today in the Archives of Internal Medicine.

23 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.

16 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.

9 Feb 2010

LExICon study evaluating laser assisted lead removal using Spectranetics laser sheath published

Spectranetics Corporation today announced publication of the four-year, retrospective LExICon (Lead Extraction in Contemporary Settings) study in the February 9th issue of the Journal of American College of Cardiology.

3 Feb 2010

Hundred millions for biotech-licence

Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).

3 Feb 2010

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

WHO pneumonia expert honored with PACE Global Leadership Award

WHO pneumonia expert Dr. Thomas Cherian will be honored by a group of the world’s leading infectious disease experts today for his pivotal work to accelerate access to vaccines preventing pneumococcal disease, the world’s leading vaccine-preventable killer of children under age five.

31 Jan 2010

Transplant tourism: Ethical issues

A recent case study by doctors at Mount Sinai Hospital in New York examined the ethical issues posed by transplant tourism, an offshoot of medical tourism, which focuses solely on transplantation surgery. Many American transplant professionals frown on the practice of transplant tourism where patients travel to countries such as China, India, and the Philippines for their transplantation.

28 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Prometheus Laboratories executes commercialization agreement with Novartis

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States.

27 Jan 2010

Sepsis News and Research

Latest Sepsis News and Research

HealthGrades America’s 50 Best Hospitals for 2010 identified

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

HealthGrades names Good Samaritan Hospital as One of America’s 50 Best Hospitals in 2010

Study says lower-cost hospitals don't have lower quality care for certain illnesses

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Multidisciplinary rounds may facilitate implementation of best clinical practices: Study

Hospital-acquired infections increase mortality rate and healthcare costs

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Viral Genetics: Company update

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

LExICon study evaluating laser assisted lead removal using Spectranetics laser sheath published

Hundred millions for biotech-licence

FDA and PATH collaborate to advance pneumococcal vaccine development for children

WHO pneumonia expert honored with PACE Global Leadership Award

Transplant tourism: Ethical issues

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Prometheus Laboratories executes commercialization agreement with Novartis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Sepsis News and Research

Latest Sepsis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in